Tzield’s Stage 3 Approval Signals the End of Insulin’s Monopoly on Type 1 Diabetes
Sanofi's Tzield just won FDA approval for stage 3 T1D, threatening insulin's 68% grip on a $28.6B market and...
FDA Approval
Regeneron Priced Otarmeni at Zero — And That’s the Most Expensive Move in Ultra-Rare Disease This Decade
Regeneron's FDA-approved gene therapy Otarmeni targets just 20–50 U.S. births yearly. Its free pricing strategy could cost every rare...